:tislelizumab

Man Yuan1,2, Ning Han1,2, Li Shu3

  • 1Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China.

Frontiers in immunology
|February 19, 2025
PubMed
概括

免疫检查点抑制剂 (ICI) 可能导致罕见的多器官损伤. 这一案例突出了tislelizumab的累积免疫相关不良事件 (irAEs),导致肺癌患者的严重损伤.